Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report
Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …
Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism …
AT Cohen, M Hamilton, A Bird, SA Mitchell, S Li… - PLoS …, 2016 - journals.plos.org
Background Historically, warfarin or aspirin have been the recommended therapeutic
options for the extended treatment (> 3 months) of VTE. Data from Phase III randomised …
options for the extended treatment (> 3 months) of VTE. Data from Phase III randomised …
[HTML][HTML] Management of venous thromboembolisms: part I. The consensus for deep vein thrombosis
Deep vein thrombosis (DVT) is a potentially catastrophic condition because thrombosis, left
untreated, can result in detrimental pulmonary embolism. Yet in the absence of thrombosis …
untreated, can result in detrimental pulmonary embolism. Yet in the absence of thrombosis …
Cerebral venous thrombosis
JM Ferro, P Canhão, DA de Sousa - La Presse Médicale, 2016 - Elsevier
Cerebral venous thrombosis (CVT) has an incidence of 1.32/100,000/years in high-income
countries, and higher in middle-and low-income countries. CVT is more frequent in infants …
countries, and higher in middle-and low-income countries. CVT is more frequent in infants …
A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES)
AIF Moreno, MJG Navarro, JO Sánchez… - European journal of …, 2016 - Elsevier
Background In patients with unprovoked venous thromboembolism (VTE), the optimal
duration of anticoagulation is anchored on estimating the risk of disease recurrence. We …
duration of anticoagulation is anchored on estimating the risk of disease recurrence. We …
Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy
YJ Lee, J Park, JS Uhm, JY Kim, HN Pak… - International journal of …, 2016 - Elsevier
Background The efficacy of oral anticoagulation therapy (OAT) has not been revealed in
atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the …
atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the …
Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen general population study
I Nørgaard, SF Nielsen, BG Nordestgaard - Clinical chemistry, 2016 - academic.oup.com
BACKGROUND Complement activation may contribute to venous thromboembolism,
including deep venous thrombosis and pulmonary embolism. We tested the hypothesis that …
including deep venous thrombosis and pulmonary embolism. We tested the hypothesis that …
[HTML][HTML] Os novos anticoagulantes no tratamento do tromboembolismo venoso
CJCS Fernandes, JL Alves Júnior… - Jornal Brasileiro de …, 2016 - SciELO Brasil
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The …
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The …
[HTML][HTML] New anticoagulants for the treatment of venous thromboembolism
CJCS Fernandes, JL Alves Júnior… - Jornal Brasileiro de …, 2016 - SciELO Brasil
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The …
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The …
Prevalence and the clinical outcome of atrial fibrillation in patients with autoimmune rheumatic disease
YS Baek, TH Kim, JS Uhm, JY Kim, HN Pak… - International journal of …, 2016 - Elsevier
Background Systemic inflammation plays an important role in the pathogenesis of atrial
fibrillation (AF). However, little evidence exists whether the risk of AF is increased in …
fibrillation (AF). However, little evidence exists whether the risk of AF is increased in …